Search results
Results from the WOW.Com Content Network
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. [9] It is given by intravenous infusion. [9]
New TYSABRI ® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Earlier Treatment with TYSABRI Demonstrated Reduction in Relapse Severity ...
Multiple sclerosis drug Tysabri is arguably the most important drug to both Biogen Idec (NAS: BIIB) and Elan (NYS: ELN) . It makes up essentially all Elan's sales after selling its drug- delivery ...
ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status - Continued Research into Risk Stratification ...
Tysabri is a monoclonal antibody that inhibits immune cells from crossing blood vessel walls to reach various tissues, including the brain. It has proven efficacy in the treatment of two serious autoimmune disorders: multiple sclerosis , and Crohn's disease .
Evidence is suggestive that this process is linked to the dissemination of PML in patients given Tysabri for MS. Following dosing unpredictability still reigns and mutations in the hinge of the antibody which may prevent Fab-arm exchange in-vivo should be considered when designing therapeutic antibodies.
Tysabri is. Biotech firms Biogen Idec and Elan announced in a press statement released Wednesday that they have filed for regulatory approval to expand the use of multiple sclerosis drug Tysabri ...
As of 2006, natalizumab (marketed as Tysabri) received a boxed warning on its packaging due to increased risk of developing progressive multifocal leukoencephalopathy (PML). Tysabri was pulled from the market in 2004, shortly after its introduction, after three cases of the rare disease were linked to its use.